Kamada Ltd. Expands Plasma Collection Capabilities in Texas with New San Antonio Center

Kamada Ltd., a leading global biopharmaceutical company, has taken a significant step forward in its mission to address rare and underserved medical conditions by opening a new plasma collection center in San Antonio, Texas. This 11,100-square-foot facility marks the company's third such center in the state, following recent openings in Houston and Beaumont. With the capacity to accommodate up to 50 donor beds, the center is expected to collect approximately 50,000 liters of plasma annually, contributing significantly to the supply of hyper-immune plasma used in critical medical treatments.

The strategic expansion is not just a milestone for Kamada but also a boon for the medical community and patients relying on plasma-derived therapeutics. Hyper-immune plasma, known for its high concentrations of specific antibodies, plays a pivotal role in reducing infection risks and mitigating disease severity, particularly for conditions like rabies exposure, lung diseases, and infectious complications in immunocompromised patients. The San Antonio center, once fully operational and upon receiving necessary approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is projected to generate between $8 million and $10 million in annual sales of normal source plasma.

Amir London, CEO of Kamada, highlighted the dual benefits of this expansion: reducing dependency on third-party suppliers and improving production costs. This move not only strengthens Kamada's position in the specialty plasma market but also ensures a more reliable supply chain for plasma-derived therapeutics, potentially benefiting industry peers and patients worldwide. With six FDA-approved products already in its portfolio, Kamada's continued investment in Texas underscores the state's growing importance as a hub for biopharmaceutical innovation and healthcare solutions.

The opening of the San Antonio plasma collection center is a testament to Kamada's commitment to addressing complex medical needs through innovation and strategic growth. As the company expands its internal plasma collection capabilities, it sets a precedent for how biopharmaceutical companies can enhance their operational efficiency while making a tangible impact on global health challenges.